Wyeth, Affymetrix, NCI, Agilent, Institute for Optical Sciences, BioForce Nanosciences, Genomics USA
Wyeth Extends Affymetrix Supply Deal for Three More Years
Wyeth has extended an ongoing microarray supply agreement with Affymetrix for three more years, Affymetrix said this week.
Under the terms of the agreement, originally signed in 1994, Wyeth will continue to use Affy’s GeneChip technology to identify new drug targets and to study genetic markers linked to therapeutic response.
Affy said Wyeth also uses its GeneChip products for disease classification and in predicting clinical progression.
No financial terms of the deal were released.
NCI Licenses Agilent's Bioinformatics Platforms
The National Cancer Institute has purchased a full site license to Agilent Technologies’ bioinformatics products, Agilent announced this week.
The NCI will use Agilent's GeneSpring GX for gene expression, CGH Analytics for comparative genomic hybridization studies, Agilent Chip Analytics for chromatin immunoprecipitation (ChIP)-on-chip data, and GeneSpring GT platforms for genotyping and SNP analysis.
Financial details were not disclosed.
Institute for Optical Sciences Purchases a BioForce Nano eNabler
BioForce Nanosciences said last week that it has placed a Nano eNabler arrayer system at the Institute for Optical Sciences in Toronto.
According to Cynthia Goh, associate director of the IOS, the institute’s research teams will be use the Nano eNabler system for “patterning surfaces at the nanoscale for biosensing and nanotechnology research.”
“We will also be inviting the groups from electrical engineering, semiconductor and surface science to come and work with the equipment,” she said.
Financial details were not discussed.
Genomics USA Moves R&D HQ to Arizona
Genomics USA recently located its research and development headquarters to Arizona, according to a report in the Arizona Daily Star.
The Illinois-based array firm’s new R&D headquarters will be located on the campus of the University of Arizona in Tucson.
Michael Hogan, chief scientific officer of Genomics USA, cited the “proximity to the biochemical and biotech research resources at the University of Arizona, the energetic local commercial biotechnology community, and access to top local research collaborators as the driving force behind the decision to put the complex in Tucson,” the paper reported.
Genomics USA could not be reached for further comment.